CD90 antibody | YKIX337.217




Rat anti Dog CD90, clone YKIX337.217 recognizes the canine Thy-1 cell surface antigen, also known as CD90. CD90 is a 20-30 kDa glycoprotein expressed by peripheral T lymphocytes, monocytes, thymocytes and vascular endothelium in dogs.
Rat anti Dog CD90, clone YKIX337.217 has been demonstrated to deplete T cells when administered in vivo (Watson et al. 1993), and to block Con A driven T cell proliferation in vitro.
Rat anti Dog CD90, clone YKIX337.217 is a useful clone for the immunophenotyping of cells and discrimination between a wide variety of lymphoproliferative disorders in dogs (Adam et al. 2009).
Rat anti Dog CD90, clone YKIX337.217 has been demonstrated to deplete T cells when administered in vivo (Watson et al. 1993), and to block Con A driven T cell proliferation in vitro.
Rat anti Dog CD90, clone YKIX337.217 is a useful clone for the immunophenotyping of cells and discrimination between a wide variety of lymphoproliferative disorders in dogs (Adam et al. 2009).
Product Details
- Target Species
- Dog
- Product Form
- Purified IgG - liquid
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
0.09% Sodium Azide - Immunogen
- Con A stimulated canine T cells.
- Approx. Protein Concentrations
- IgG concentration 1.0 mg/ml
- Fusion Partners
- Spleen cells from immunised DA rats were fused with cells of the rat Y3/Ag1.2.3 myeloma cell line.
Storage Information
- Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Shelf Life
- 18 months from date of despatch.
More Information
- Regulatory
- For research purposes only
Applications of CD90 antibody
Application Name | Verified | Min Dilution | Max Dilution |
---|---|---|---|
Flow Cytometry | 1/50 | ||
Immunoprecipitation |
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
Copyright © 2019 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
Description | Product Code | Pack Size | Applications | List Price | Quantity |
---|---|---|---|---|---|
Goat anti Rat IgG:Alk. Phos. (Mouse Adsorbed) | STAR131A | 1 ml | C E P WB | ||
Goat anti Rat IgG:Biotin (Mouse Adsorbed) | STAR131B | 0.5 mg | C E IF P WB | ||
Rabbit F(ab')2 anti Rat IgG:Dylight®800 | STAR16D800GA | 0.1 mg | F IF WB | ||
Rabbit F(ab')2 anti Rat IgG:FITC | STAR17B | 1 mg | F | ||
Rabbit F(ab')2 anti Rat IgG:HRP | STAR21B | 1 mg | C E P RE | ||
Goat F(ab')2 anti Rat IgG:FITC (Mouse Adsorbed) | STAR69 | 0.5 ml | F | ||
Goat anti Rat IgG:DyLight®649 (Mouse Adsorbed) | STAR71D649GA | 0.1 mg | F IF | ||
Goat anti Rat IgG:Dylight®800 (Mouse Adsorbed) | STAR71D800GA | 0.1 mg | F IF WB | ||
Goat anti Rat IgG:HRP (Mouse Adsorbed) | STAR72 | 0.5 mg | C E P | ||
Goat F(ab')2 anti Rat IgG:RPE (Mouse Adsorbed) | STAR73 | 0.5 ml | F |
Negative Isotype Controls Available
Description | Product Code | Pack Size | Applications | List Price | Quantity |
---|---|---|---|---|---|
Rat IgG2b Negative Control | MCA6006GA | 0.1 mg | F |
Product Specific References
References for CD90 antibody
-
Cobbold, S. & Metcalfe, S. (1994) Monoclonal antibodies that define canine homologues of human CD antigens: summary of the First International Canine Leukocyte Antigen Workshop (CLAW).
Tissue Antigens. 43 (3): 137-54. -
Carneiro, C.M. et al. (2007) Differential impact of metacyclic and blood trypomastigotes on parasitological, serological and phenotypic features triggered during acute Trypanosoma cruzi infection in dogs.
Acta Trop. 101: 120-9. -
Kang, J.W. et al. (2008) Soluble factors-mediated immunomodulatory effects of canine adipose tissue-derived mesenchymal stem cells.
Stem Cells Dev. 17: 681-93. -
Sanchez, M.A. et al. (2004) Organ-specific immunity in canine visceral leishmaniasis: analysis of symptomatic and asymptomatic dogs naturally infected with Leishmania chagasi.
Am J Trop Med Hyg. 70: 618-24. -
Giunchetti, R.C. et al. (2008) Histopathology, parasite density and cell phenotypes of the popliteal lymph node in canine visceral leishmaniasis.
Vet Immunol Immunopathol. 121: 23-33. -
Reis, A.B.
(2005) Establishment of a microplate assay for flow cytometric assessment and it is use for the evaluation of age-related phenotypic changes in canine whole blood leukocytes.
Vet Immunol Immunopathol. 103: 173-85. -
Bearden, R.N. et al. (2017) In-vitro characterization of canine multipotent stromal cells isolated from synovium, bone marrow, and adipose tissue: a donor-matched comparative study.
Stem Cell Res Ther. 8 (1): 218. -
Saulnier, N. et al. (2016) Canine Placenta: A promising potential source of highly proliferative and immunomodulatory Mesenchymal Stromal Cells?
Veterinary Immunology and Immunopathology. Feb 11 [Epub ahead of print] -
Nishimura, T. et al. (2017) Feeder-independent canine induced pluripotent stem cells maintained under serum-free conditions.
Mol Reprod Dev. Feb 27. [Epub ahead of print] -
Lee, J. et al. (2016) Chondrogenic potential and anti-senescence effect of hypoxia on canine adipose mesenchymal stem cells.
Vet Res Commun. 40 (1): 1-10. -
Rathore, K. & Cekanova, M. (2015) Effects of environmental carcinogen benzo(a)pyrene on canine adipose-derived mesenchymal stem cells.
Res Vet Sci. 103: 34-43. -
Trindade, A.B. et al. (2017) Mesenchymal-like stem cells in canine ovary show high differentiation potential.
Cell Prolif. 50 (6)Oct 08 [Epub ahead of print].
Further Reading
-
Watson, C.J. et al. (1993) CD4 and CD8 monoclonal antibody therapy: strategies to prolong renal allograft survival in the dog.
Br J Surg. 80: 1389-92.